- Home
- VIRX vs ALCE Comparison
VIRX vs ALCE Comparison
Compare VIRX & ALCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIRX
- ALCE
- Stock Information
- Founded
- VIRX 2007
- ALCE 2019
- Country
- VIRX United States
- ALCE United States
- Employees
- VIRX N/A
- ALCE N/A
- Industry
- VIRX Biotechnology: Pharmaceutical Preparations
- ALCE Power Generation
- Sector
- VIRX Health Care
- ALCE Utilities
- Exchange
- VIRX Nasdaq
- ALCE Nasdaq
- Market Cap
- VIRX 7.7M
- ALCE 8.6M
- IPO Year
- VIRX N/A
- ALCE N/A
- Fundamental
- Price
- VIRX $0.16
- ALCE $1.36
- Analyst Decision
- VIRX Buy
- ALCE
- Analyst Count
- VIRX 4
- ALCE 0
- Target Price
- VIRX $5.00
- ALCE N/A
- AVG Volume (30 Days)
- VIRX 2.5M
- ALCE 743.0K
- Earning Date
- VIRX 11-13-2024
- ALCE 12-03-2024
- Dividend Yield
- VIRX N/A
- ALCE N/A
- EPS Growth
- VIRX N/A
- ALCE N/A
- EPS
- VIRX N/A
- ALCE N/A
- Revenue
- VIRX N/A
- ALCE N/A
- Revenue This Year
- VIRX N/A
- ALCE N/A
- Revenue Next Year
- VIRX N/A
- ALCE N/A
- P/E Ratio
- VIRX N/A
- ALCE N/A
- Revenue Growth
- VIRX N/A
- ALCE N/A
- 52 Week Low
- VIRX $0.13
- ALCE $1.16
- 52 Week High
- VIRX $1.31
- ALCE $266.50
- Technical
- Relative Strength Index (RSI)
- VIRX 32.53
- ALCE 21.70
- Support Level
- VIRX $0.14
- ALCE $1.16
- Resistance Level
- VIRX $0.21
- ALCE $2.20
- Average True Range (ATR)
- VIRX 0.01
- ALCE 0.29
- MACD
- VIRX -0.00
- ALCE -0.01
- Stochastic Oscillator
- VIRX 43.86
- ALCE 11.88
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
About ALCE Alternus Clean Energy Inc.
Alternus Clean Energy Inc is an international independent clean energy producer. It develops, installs, owns and operates a diverse portfolio of utility-scale solar photovoltaic power stations (PV parks) in Europe and the USA as a long-term owner. The solar parks benefit from long-term government offtake contracts and/or Power Purchase Agreements (PPAs) with investment grade off-takers, plus energy sales to local power grids. It has approximately 8 operating parks, a total of 44 MWp in operation.